Skip to main content
Premium Trial:

Request an Annual Quote

Phenomics Health Acquires Precera Pharmacometabolomic Technology

NEW YORK — Bioinformatics firm Phenomics Health said today that it has acquired the pharmacometabolomic technology portfolio of Precera Bioscience.

Terms of the deal were not disclosed.

The patented technology, called PrecisMed, is designed to analyze blood from a finger prick to detect, measure, and assess over 200 medications in a patient's bloodstream. Ann Arbor, Michigan-based Phenomics said it will incorporate the technology into its own pharmacogenomics platform for reviewing a patient's potential and actual response to medications.

"Our newly enhanced platform integrates Phenomics Health's disease-drug response network discoveries and patient pharmacometabolomic profiles to enhance the precision and predictability of medication selection," Phenomics Cofounder, CSO, and CTO Brian Athey said in a statement. "The information gathered through its use could change the direction of how clinicians prescribe and manage medications, greatly improving a patient's response."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.